Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.150
AS - Asia 9.500
EU - Europa 7.894
SA - Sud America 1.473
Continente sconosciuto - Info sul continente non disponibili 762
AF - Africa 262
OC - Oceania 30
Totale 38.071
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.176
SG - Singapore 3.125
IT - Italia 2.596
CN - Cina 2.022
VN - Vietnam 1.709
BR - Brasile 1.093
HK - Hong Kong 1.080
DE - Germania 1.023
RU - Federazione Russa 996
CA - Canada 721
IE - Irlanda 656
SE - Svezia 641
GB - Regno Unito 405
FR - Francia 360
UA - Ucraina 316
IN - India 302
BD - Bangladesh 217
FI - Finlandia 182
PL - Polonia 163
KR - Corea 155
AR - Argentina 151
ID - Indonesia 145
ES - Italia 128
TR - Turchia 124
NL - Olanda 101
JP - Giappone 98
IQ - Iraq 93
ZA - Sudafrica 86
MX - Messico 81
PK - Pakistan 81
BE - Belgio 70
CH - Svizzera 61
EC - Ecuador 48
AT - Austria 47
CO - Colombia 46
MA - Marocco 45
SA - Arabia Saudita 44
UZ - Uzbekistan 44
PH - Filippine 43
VE - Venezuela 38
DK - Danimarca 36
CL - Cile 29
KE - Kenya 28
PE - Perù 28
LT - Lituania 27
TN - Tunisia 26
CR - Costa Rica 25
PY - Paraguay 24
AU - Australia 23
HN - Honduras 21
JM - Giamaica 20
NP - Nepal 19
TT - Trinidad e Tobago 19
ET - Etiopia 18
EG - Egitto 17
JO - Giordania 17
SV - El Salvador 17
TW - Taiwan 17
IR - Iran 16
AE - Emirati Arabi Uniti 15
AZ - Azerbaigian 15
MY - Malesia 15
PR - Porto Rico 15
TH - Thailandia 15
EU - Europa 14
NI - Nicaragua 14
CW - ???statistics.table.value.countryCode.CW??? 12
GT - Guatemala 10
OM - Oman 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
DO - Repubblica Dominicana 9
PS - Palestinian Territory 9
GR - Grecia 8
IL - Israele 8
KZ - Kazakistan 8
RO - Romania 8
MU - Mauritius 7
AL - Albania 6
AO - Angola 6
EE - Estonia 6
GE - Georgia 6
KG - Kirghizistan 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
PA - Panama 6
PT - Portogallo 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
MD - Moldavia 5
NG - Nigeria 5
AM - Armenia 4
BH - Bahrain 4
LB - Libano 4
MK - Macedonia 4
MO - Macao, regione amministrativa speciale della Cina 4
RS - Serbia 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
Totale 37.261
Salva come PNG Salva come JPEG
Città #
Ashburn 2.030
Ann Arbor 1.939
Singapore 1.734
San Jose 1.132
Hong Kong 1.046
Milan 965
Woodbridge 728
Fairfield 689
Frankfurt am Main 657
Dublin 640
Chandler 603
Ho Chi Minh City 521
Council Bluffs 484
Houston 464
Wilmington 449
Hanoi 438
Toronto 433
New York 421
Dallas 412
Los Angeles 384
Santa Clara 311
Beijing 303
Chicago 281
Seattle 278
Jacksonville 273
Hefei 263
Cambridge 249
Dearborn 247
The Dalles 226
Princeton 176
Seoul 139
Shanghai 134
Lauterbourg 128
Nanjing 125
São Paulo 125
Boardman 122
Rome 121
Buffalo 120
Columbus 119
Phoenix 103
Munich 101
Moscow 94
Jakarta 93
Altamura 83
Lawrence 80
Tokyo 80
Da Nang 78
Helsinki 78
Montreal 72
Warsaw 72
Lodz 70
Atlanta 68
Brooklyn 65
Orem 63
Haiphong 62
Brussels 61
Denver 58
London 57
San Diego 54
Johannesburg 51
Guangzhou 49
Rio de Janeiro 47
Nuremberg 45
Zurich 45
Lachine 44
Chennai 42
Washington 42
Kent 41
Fremont 40
Hải Dương 40
Poplar 40
Turku 40
Staranzano 39
Stockholm 39
Turin 38
Lissone 37
Baghdad 36
Shenyang 36
Tashkent 36
Boston 34
Desio 34
Nanchang 33
Amsterdam 31
Andover 31
North Bergen 31
Biên Hòa 30
Salt Lake City 30
San Francisco 30
Changsha 29
Lahore 29
Ottawa 29
Romola 29
Newark 28
Philadelphia 28
Pune 28
Ankara 27
Göttingen 27
Jinan 27
Manchester 27
Monza 26
Totale 22.846
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 600
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 494
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 479
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 477
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 465
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 461
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 460
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 445
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 444
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 443
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 428
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 421
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 420
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 419
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 411
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 410
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 405
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 399
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 398
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 390
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 380
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 377
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 377
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 375
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 373
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 370
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 368
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 366
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 365
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 361
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 358
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 358
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 356
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 355
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 353
Dual kinase targeting in leukemia 349
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 346
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 345
Inhibition of RET tyrosine kinase by SU5416 342
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 340
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 337
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 336
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 335
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 334
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 333
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 331
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 330
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 323
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 321
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 318
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 317
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 316
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 313
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 312
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 310
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 308
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 305
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 302
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 297
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 296
Expression, purification, and inhibition of human RET tyrosine kinase 296
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 294
We shall overcome (drug resistance) some day 292
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 289
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 286
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 281
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 279
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 277
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 269
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 267
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 267
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 266
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 266
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 264
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 264
Novel targeted therapeutics for MEN2 264
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 264
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 263
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 263
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 260
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 259
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 258
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 257
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 256
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 253
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 251
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 247
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 246
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 245
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 245
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 244
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 242
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 239
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 237
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 236
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 232
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 231
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 226
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR 225
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia 225
Totale 32.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.477
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022914 0 0 0 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20255.508 275 476 319 278 440 200 369 193 548 880 492 1.038
2025/202614.949 1.935 1.030 1.206 1.673 1.644 753 2.020 617 1.126 1.284 817 844
2026/20274.162 495 664 1.351 1.652 0 0 0 0 0 0 0 0
Totale 38.071